Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees.

Robinson, William E.; Montefiori, D. C.; Mitchell, W M; Prince, Alfred M.; Alter, H. J.; Dreesman, G R; Eichberg, Jorg W.

doi:10.1073/pnas.86.12.4710

Cited by 94 publications

(40 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, antibodies reactive with monomeric gp120 as measured here do not necessarily correlate with neutralizing antibody titers 39 and could in principle also harbor enhancing activity. 40,41 Although influence of enhancing antibodies cannot be ruled out, high anti-gp120 titers may well be consequence instead of cause of high viremia. Supporting the latter scenario, we provide evidence that patients with high anti-gp120 titers were subject to higher viral replication, which coincided with increased immune deficiency impairing novel antibody responses and viral defense mechanisms.…”

Section: Discussionmentioning

confidence: 99%

Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point

Trkola¹

2004

Blood

View full text Add to dashboard Cite

We analyzed the humoral immune response in 46 patients following structured treatment interruption (STI) to investigate the general potential of therapeutic vaccination in chronic HIV-1 infection. Evoked antibody titer increases to glycoprotein 120 (gp120) and p24 were low during 4 short-term STIs and only reached significance during a fifth long-term interruption. Although induction of binding antibodies to viral antigens was not associated with potent suppression of viremia, we observed that individuals with a rapid and high response to p24, and to a lesser extent also to gp120, lowered their viral set points significantly. Of note, the increase of the anti-p24 response correlated with specific CD4 T helper frequency to this antigen. Despite induction of binding antibody responses, which correlated with improved viral control, the increase in neutralizing activity was marginal and did not lead to this enhanced viral suppression. However, a subgroup of patients who potently suppressed viremia independently of STI had significantly higher pre-existing neutralization titers, suggesting a role of humoral immunity in conferring potent protection. In summary, measuring the kinetics of antibody responses provided a marker to validate the responsiveness and capacities of the immune system of HIV-1-infected individuals and reflected the patients' ability to decrease viral set points.

show abstract

Section: Discussionmentioning

confidence: 99%

Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point

Trkola¹

2004

Blood

View full text Add to dashboard Cite

show abstract

“…However, they also may contain structures developed by the virus to evade the immune system, such as suppressive epitopes or masking carbohydrates, or structures that elicit deleterious effects such as enhancing antibodies that increase viral infectivity (1)(2)(3)(4) or antibodies or T cells that may contribute to immunodeficiency in the case of HIV (5)(6)(7)(8). In addition, for a retrovirus such as HIV, concerns about the safety of live attenuated or even killed whole viral vaccines may make them unacceptable to many potential recipients.…”

Section: Introductionmentioning

confidence: 99%

Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types.

et al. 1991

View full text Add to dashboard Cite

To make synthetic peptide vaccines effective in a broad population of outbred humans, one would have to incorporate enough antigenic determinants to elicit recognition by T cells of most HLA types. We have previously defined multideterminant regions of the human immunodeficiency virus (HIV) envelope that include overlapping determinants seen by proliferating T cells of three or four haplotypes of mice. We have now tested the hypothesis that synthetic peptides encompassing such multideterminant regions will be recognized by T cells of multiple murine MHC types as well as by human T cells representing multiple HLA types. Six such peptides of 20-33 residues in length were prepared, and tested for their ability to stimulate T cells from mice of four distinct MHC types immunized with recombinant envelope protein rgpl6O, as well as from 42 HIVinfected humans of different HLA types. Results identify several such peptides that are broadly recognized by mice of four H-2 types and by 52-73% of infected humans who still retain IL-2 productive responses to control recall antigens such as influenza A virus or tetanus toxoid. 86% of such infected donors tested against at least three peptides respond to at least one of the six peptides, and 77% of an additional group of seropositives respond to a mixture of the peptides. Moreover, the peptides can be used to immunize mice to elicit T cells reactive with the intact HIV envelope protein. These peptides therefore may be useful for both vaccine development in the broad human population, and diagnostic or prognostic use. (J. Clin. Invest.

show abstract

“…In addition to DENV, other infections such as influenza (25), HIV (26,27), and severe acute respiratory syndromecoronavirus (28) have been reported to generate Ag-specific Ab responses that can enhance infection and disease progression. In the case of HIV and influenza, it has been hypothesized that vaccination with the wrong virus could lead to enhanced infection within the vaccinated population (26).…”

Section: Discussionmentioning

confidence: 99%

Single-Cell Analysis of B Cell/Antibody Cross-Reactivity Using a Novel Multicolor FluoroSpot Assay

Hadjilaou

Green

Coloma

et al. 2015

The Journal of Immunology

View full text Add to dashboard Cite

Dengue is a major public health problem globally. It is caused by four antigenically distinct serotypes of dengue virus (DENV1–4), and although serotype-specific and strongly neutralizing cross-reactive immune responses against the four DENV serotypes are thought to be protective, subneutralizing Abs can contribute to increased disease severity upon secondary infection with a different DENV serotype. Understanding the breadth of the immune response in natural DENV infections and in vaccinees is crucial for determining the correlates of protection or disease severity. Transformation of B cell populations to generate mAbs and ELISPOT assays have been used to determine B cell and Ab specificity to DENV; however, both methods have technical limitations. We therefore modified the conventional ELISPOT to develop a Quad-Color FluoroSpot to provide a means of examining B cell/Ab serotype specificity and cross-reactivity on a single-cell basis. Abs secreted by B cells are captured by an Fc-specific Ab on a filter plate. Subsequently, standardized concentrations of all four DENV serotypes are added to allow equal stoichiometry for Ag binding. After washing, the spots, representing individual B cells, are visualized using four fluorescently labeled DENV serotype-specific detection mAbs. This method can be used to better understand the breadth and magnitude of B cell responses following primary and secondary DENV infection or vaccination and their role as immune correlates of protection from subsequent DENV infections. Furthermore, the Quad-Color FluoroSpot assay can be applied to other diseases caused by multiple pathogen serotypes in which determining the serotype or subtype-specific B cell response is important.

show abstract

Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees.

Abstract: Based on recent reports of antibody-dependent enhancement of human immunodeficiency virus type 1

Cited by 94 publications

References 20 publications

Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point

Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point

Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types.

Single-Cell Analysis of B Cell/Antibody Cross-Reactivity Using a Novel Multicolor FluoroSpot Assay

Contact Info

Product

Resources

About